These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30767720)

  • 1. Iatrogenic CNS demyelination in the era of modern biologics.
    Kumar N; Abboud H
    Mult Scler; 2019 Jul; 25(8):1079-1085. PubMed ID: 30767720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic.
    Kelly H; Johnson J; Jakubecz C; Serra A; Abboud H
    J Neuroimmunol; 2022 Sep; 370():577928. PubMed ID: 35853358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.
    Kunchok A; Aksamit AJ; Davis JM; Kantarci OH; Keegan BM; Pittock SJ; Weinshenker BG; McKeon A
    JAMA Neurol; 2020 Aug; 77(8):937-946. PubMed ID: 32421186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes.
    Karussis D; Petrou P
    Autoimmun Rev; 2014 Mar; 13(3):215-24. PubMed ID: 24514081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese.
    Chan KH; Lee R; Lee JC; Tse AC; Pang SY; Lau GK; Teo KC; Ho PW
    J Neuroimmunol; 2013 Sep; 262(1-2):100-5. PubMed ID: 23838529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
    Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M
    Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings.
    Rimkus CM; Schoeps VA; Boaventura M; Godoy LF; Apostolos-Pereira SL; Calich AL; Callegaro D; Lucato LT; Rovira A; Sastre-Garriga J; Leite CDC
    Mult Scler Relat Disord; 2021 Oct; 55():103146. PubMed ID: 34332456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
    Karussis D
    J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor.
    Chey SY; Kermode AG
    Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211070750. PubMed ID: 35024163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
    Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathy.
    Ciron J; Carra-Dallière C; Ayrignac X; Neau JP; Maubeuge N; Labauge P
    Mult Scler Relat Disord; 2019 Jan; 27():223-225. PubMed ID: 30414563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iatrogenic demyelinating disorders: New insights, new culprits.
    Abboud H
    Mult Scler; 2020 Aug; 26(9):1129-1130. PubMed ID: 31845617
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-MS autoimmune demyelination.
    Cikes N; Bosnic D; Sentic M
    Clin Neurol Neurosurg; 2008 Nov; 110(9):905-12. PubMed ID: 18928881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    Cortese R; Prosperini L; Stasolla A; Haggiag S; Villani V; Simone IL; Gasperini C; Tortorella C
    J Neurol; 2021 Aug; 268(8):2895-2899. PubMed ID: 33611609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.
    Oliveira MCB; de Brito MH; Simabukuro MM
    Front Neurol; 2020; 11():538695. PubMed ID: 33362680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
    Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
    Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.
    Dale RC; de Sousa C; Chong WK; Cox TC; Harding B; Neville BG
    Brain; 2000 Dec; 123 Pt 12():2407-22. PubMed ID: 11099444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
    Yang Y; Wu WP; Huang DH; Wu L
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances.
    Costanza M
    J Immunol Res; 2019; 2019():4204512. PubMed ID: 31205957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.
    Singh S; Kumar N; Loftus EV; Kane SV
    Inflamm Bowel Dis; 2013; 19(4):864-72. PubMed ID: 22552994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.